Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Treating hypertension in patients receiving BTK inhibitors

Mazyar Shadman • 10 Jun 2022
EHA 2022
Chronic Lymphocytic Leukemia General Leukemia Acalabrutinib Ibrutinib

Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center, Seattle, WA, shares results from a study investigating the treatment of hypertension in patients receiving BTK inhibitors. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Mazyar Shadman

1:17
Dose reductions to manage AEs of ibrutinib treatment for CLL
Mazyar Shadman • 10 Dec 2023
1:32
CD20-targeted CAR T-Cell therapy for patients with indolent B-cell NHL
Mazyar Shadman • 10 Dec 2023
1:06
Zanubrutinib in patients with B-cell malignancies who are acalabrutinib-intolerant
Mazyar Shadman • 10 Dec 2023
3:09
Retrospective analysis of clinical outcomes in pts with LBCL receiving CAR-T or autoSCT while in CR
Mazyar Shadman • 10 Dec 2023

Related Videos

1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
4:07
Pooled fecal allogeneic microbiotherapy to treat refractory gastrointestinal acute GvHD
Florent Malard • 11 Apr 2024
5:23
Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD
Mohamad Mohty • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals